

DWP223: A Selective DNA Polymerase Theta Inhibitor

Daewoong Pharmaceutical



ONCOLOGY	Preclinical
Product Type	Small molecules
Indication	Oncology
Target	DNA polymerase theta
MoA(Mechanism of Action)	DNA polymerase theta inhibitor
Competitiveness	<ul style="list-style-type: none"> • Demonstrates strong <i>in vivo</i> efficacy at lower doses • Exhibits high synergy with low-dose olaparib and effectively targets PARP inhibitor-resistant cancers • Possesses a favorable PK profile, with potential for once-daily dosing in clinical settings • Offers potential for wide safety margins
Development Stage	Preclinical
Route of Administration	PO

Any unauthorized distribution or reproduction of this material is strictly prohibited.